Rsv Clinical Trials
Here are the 6 most popular medical studies for rsv
Lenacapavir for HIV Infection
This trial will study the effectiveness of a new drug, lenacapavir, in preventing HIV infection in people who are at risk. The trial will have two parts: a cross-sectional study to estimate the background HIV infection rate, and a double-blind, randomized study to study the drug.
DOR/ISL for HIV
This trial is testing a new once-daily pill for HIV-1 infection. The pill contains two drugs, doravirine and islatravir. The trial will compare the new pill to a currently available pill that contains three drugs, bictegravir, emtricitabine, and tenofovir alafenamide. The trial will last 48 weeks and the primary outcome will be the percentage of participants with HIV-1 RNA <50 copies/mL at Week 48.
Respiratory Syncytial Virus Clinical Trials
View 27 Respiratory Syncytial Virus medical studies.
COVID-19 Clinical Trials
View 9 COVID-19 medical studies.
Phase 3 Rsv Clinical Trials
View 100 phase 3 rsv medical studies.
Rsv Clinical Trials With No Placebo
View 100 rsv medical studies that do not have a placebo group.
RSV Vaccine for Respiratory Syncytial Virus
This trial will assess the safety and long-term effectiveness of a new RSV vaccine in adults aged 60+. The study will also evaluate the safety and effectiveness of additional doses of the vaccine given at different intervals.
Paid Rsv Clinical Trials
View 100 rsv medical studies that offer remuneration.
View More Rsv Trials
See another 71 many medical studies focused on rsv.
Frequently Asked Questions
Introduction to rsv
What are the top hospitals conducting rsv research?
In the realm of respiratory syncytial virus (RSV) clinical trials, several hospitals are leading the charge in finding effective treatments for this common and potentially severe illness. At Cincinnati Children's Hospital Medical Center in Cincinnati, researchers are currently engaged in six active RSV trials, building upon their five previous studies since embarking on their first trial back in 2007. The dedication to understanding and combatting RSV is not limited to a single location, as GSK Investigational Sites across various cities have also made significant contributions. In San Antonio, four ongoing RSV trials are underway alongside seven previously conducted studies that date back to their initial investigation of this condition in 2019. Similarly, at the GSK Investigational Site in Sherbrooke, Quebec, another four active RSV trials complement their track record of seven completed studies since commencing research efforts only last year in 2021.
Expanding further into Texas territory reveals more noteworthy advancements. In Dallas' GSK Investigational Site alone, there are presently four ongoing clinical tests focused on combating RSV while sharing a close collaboration with just five past investigations recorded starting from 2020 onwards. Not too far away lies Fort Myers' own GSK Investigational Site where they join the ranks with an equal number of ongoing rsv inquiries totaling four; though relatively newer than most counterparts given that it was only recently established its presence by initiating first-ever involvement through conducting rsv experimentalo Texas territory reveals more noteworthy advancements. In Dallas' GSK Investigational Site alone, there are presently four ongoing clinical tests focused on combating RSV while sharing a close collaboration with just five past investigations recorded starting from 2020 onwards. Not too far away lies Fort Myers' own GSK Investigational Site where they join the ranks with an equal number of ongoing rsv inquiries totaling four; though relatively newer than most counterparts given that it was only recently established its presence by initiating first-ever involvement through conducting rsv experimental attempts beginning from early-stage exploration during 2021.
These dynamic hospital centers represent shining beacons of hope for patients affected by respiratory syncytial virus as they tirelessly continue striving towards better preventive measures and treatments against this pervasive infection. Through these collective efforts nationwide - all around different locations - progress is being made step-by-step toward curbing the impact and improving outcomes related to RSV cases which will ultimately lead us closer towards minimizing its burden on global health systems worldwide
Which are the best cities for rsv clinical trials?
In the realm of RSV clinical trials, several cities emerge as prominent hubs for research and development. Los Angeles, California takes the lead with 28 active trials exploring various treatments such as RSVpreF, Oral Lenacapavir (LEN), DOR/ISL, among others. New York, New York follows closely behind with 24 ongoing studies investigating interventions like S-217622 plus standard of care (SOC), Piperacillin-tazobactam, Glecaprevir/Pibrentasvir (GLE/PIB), and more. Baltimore, Maryland also plays a crucial role in advancing RSV treatment options through its 23 active trials focused on BCG TICE Vaccine, Pritelivir, RSV ΔNS2/Δ1313/I1314L Vaccine, and other innovative approaches. These cities contribute significantly to the collective effort in finding effective solutions against RSV while offering individuals affected by this condition access to cutting-edge clinical trials that may improve their health outcomes.
Which are the top treatments for rsv being explored in clinical trials?
Clinical trials are shedding light on potential breakthroughs in the treatment of RSV (respiratory syncytial virus). Among the top contenders is palivizumab, a monoclonal antibody currently being investigated in several promising trials. Another noteworthy candidate is nirsevimab, an investigational fusion protein that has shown promise in early clinical studies. Additionally, there are ongoing trials exploring the efficacy of REGN2222, a potent antiviral antibody against RSV. These treatments hold great potential for revolutionizing the management of RSV and providing hope for those affected by this respiratory infection.
What are the most recent clinical trials for rsv?
Recent clinical trials have brought forth promising advancements in the field of RSV treatment. Notably, Cohort A and RSV_IC_1 groups have undergone Phase 2 trials, showing potential for improved therapeutic options. In addition, a Phase 3 trial has explored the co-administration of RSV+ HZ/su as a means to combat RSV infection. Another Phase 3 study focused on evaluating the effectiveness of low dose RSVpreF against this respiratory virus. Furthermore, Group 2 underwent a Phase 2 trial with encouraging results. These latest clinical trials pave the way towards enhanced management and prevention strategies for RSV infections in patients across different cohorts.
What rsv clinical trials were recently completed?
Recently, several notable clinical trials focusing on RSV (Respiratory Syncytial Virus) have reached completion, showcasing exciting progress in the field. In July 2022, Blue Lake Biotechnology Inc. concluded a trial investigating the CPI-RSV-F Vaccine (BLB-201). Moreover, GlaxoSmithKline wrapped up two important trials: one examining the RSVPreF3 OA investigational vaccine in October 2021 and another exploring the Flu3 OA investigational vaccine in October 2021 and another exploring the Flu D-QIV vaccine in September 2021. Additionally, their RSV MAT study was completed in August 2021. While MedImmune LLC's MEDI8897 trials were finalized back in July 2019, these collective efforts highlight ongoing research to combat RSV and bring us closer to effective treatments for this respiratory virus.